

Paulson, Iyer et al.  
 Journal of Investigative Dermatology  
 “Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage“

**Supplemental table**

Characteristic	Multivariate	
	HR	95% CI
<b>STAGE AT DIAGNOSIS (AJCC 7<sup>th</sup> edition)</b>		
<i>Stage IB (vs. IA)</i>	15.6*	2.1-117.4
<i>Stage IIA (vs. IA)</i>	10.9*	1.2-99.6
<i>Stage IIB (vs. IA)</i>	14.5*	1.5-135.9
<i>Stage IIIA (vs. IA)</i>	25.3*	3.4-189.8
<i>Stage IIIB (vs. IA)</i>	43.7*	6.1-313.6
<i>Stage IV (vs. IA)</i>	75.7*	10.2-560.3
<b>SEX</b>		
<i>Female (vs. Male)</i>	0.9	0.6-1.4
<b>AGE AT DIAGNOSIS</b>		
<i>Age (per year older)</i>	1.00	0.99-1.02
<b>SYSTEMIC IMMUNE SUPPRESSION</b>		
<i>Immunosuppressed (vs. not)</i>	4.2*	2.4-7.4

**Supplemental Table 1: Multivariate Competing Risk Regression Analysis Demonstrate Immune Suppression Is an Predictor of Poor Merkel Cell Carcinoma Specific Survival Independent of stage by current AJCC criteria.** Multivariate analysis including all listed variables. HR = hazard ratio; \* indicates  $p < 0.05$ . CI = confidence interval. N = 395 (76 patients with local-regional-distant stage lacked sufficient information for AJCC 7<sup>th</sup> edition staging). Staging as per AJCC 7<sup>th</sup> Edition guidelines.